No Cover Image

Journal article 132 views 33 downloads

Mitochondrial DNA abnormalities provide mechanistic insight and predict reactive oxygen species-stimulating drug efficacy

Tarek Zaidieh, James R. Smith, Karen E. Ball, Qian An

BMC Cancer, Volume: 21, Issue: 1

Swansea University Author: Tarek Zaidieh

  • 60410.VOR.pdf

    PDF | Version of Record

    © The Author(s). 2021, corrected publication 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made

    Download (2.7MB)

Check full text

DOI (Published version): 10.1186/s12885-021-08155-2

Abstract

Associations between mitochondrial genetic abnormalities (variations and copy number, i.e. mtDNAcn, change) and elevated ROS have been reported in cancer compared to normal cells. Since excessive levels of ROS can trigger apoptosis, treating cancer cells with ROS-stimulating agents may enhance their...

Full description

Published in: BMC Cancer
ISSN: 1471-2407
Published: Springer Science and Business Media LLC 2021
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa60410
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: Associations between mitochondrial genetic abnormalities (variations and copy number, i.e. mtDNAcn, change) and elevated ROS have been reported in cancer compared to normal cells. Since excessive levels of ROS can trigger apoptosis, treating cancer cells with ROS-stimulating agents may enhance their death. This study aimed to investigate the link between baseline ROS levels and mitochondrial genetic abnormalities, and how mtDNA abnormalities might be used to predict cancer cells’ response to ROS-stimulating therapy.
Keywords: Mitochondrial DNA, MtDNA variations, MtDNA copy number, Reactive oxygen species, Cisplatin, Dequalinium chloride hydrate, ROS-stimulating therapy, Cancer biomarker
College: Faculty of Medicine, Health and Life Sciences
Funders: University of Portsmouth; Cara
Issue: 1

Similar Items